Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2024-209459

Published: 2024

Journal Articles

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Chunmei Yang, Liping Mao, Juying Wei, Wanzhuo Xie, Xingnong Ye, Min Yang, Jian Huang, De Zhou, Liya Ma, Yinjun Lou, Huafeng Wang, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6518.

https://doi.org/10.1182/blood-2024-202298

Published: 2024

Journal Articles

Efficacy and Safety of Glofitamab Combined with Tislelizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results

De Zhou, Wenjuan Yu, Xin Huang, Juying Wei, Liping Mao, Xingnong Ye, Ehsan Ghoushi, Xiaolong Zheng, Xuelian Hu, Jie Jin, Wanzhuo Xie, Hongyan Tong

Blood (2024) 144 (Supplement 1): 6496.

https://doi.org/10.1182/blood-2024-198413

Published: 2024

Journal Articles

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Haiyan Zhang, Xiang Zhang, Jinghan Wang, Xuewu Zhang, Yunfei Lv, Yanan Zhu, Juying Wei, Min Yang, Gaixiang Xu, Xingnong Ye, Yinjun Lou, Chunmei Yang, Haitao Meng, Wanzhuo Xie, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6468.

https://doi.org/10.1182/blood-2024-205687

Published: 2024

Journal Articles

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Xuewu Zhang, Yanan Zhu, Xiang Zhang, Xingnong Ye, Gaixiang Xu, Liya Ma, Yanling Ren, Liping Mao, Min Yang, Chunmei Yang, Juying Wei, Yinjun Lou, Wenyuan Mai, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2024-204442

Published: 2024

Journal Articles

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Yiyi Yao, Yile Zhou, Nanfang Zhuo, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Liping Mao, Hongyan Tong, Jiejing Qian, Min Yang, Wenjuan Yu, De Zhou, Jian Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 7485.

https://doi.org/10.1182/blood-2024-204411

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome in Combination with Cytarabine and Venetoclax (MAV) Regimen in Relapsed or Refractory Acute Myeloid Leukemia

Huafeng Wang, Yile Zhou, Min Yang, De Zhou, Jian Huang, Liping Mao, Yinjun Lou, Wanzhuo Xie, Jie Jin

Blood (2024) 144 (Supplement 1): 6076.

https://doi.org/10.1182/blood-2024-210439

Published: 2024

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Blood (2024) 144 (Supplement 1): 836.

https://doi.org/10.1182/blood-2024-208355

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Ying Huang, Yanan Zhu, Xiang Zhang, Xuewu Zhang, Juying Wei, Xingnong Ye, Yinjun Lou, Min Yang, Chunmei Yang, Wanzhuo Xie, Haitao Meng, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2024-205842

Published: 2024

Journal Articles

Effects and Molecular Mechanism of Inhibiting p53 Signaling Pathway By NSUN6 on the Resistance to BCL-2 Inhibitor for Diffuse Large B-Cell Lymphoma

Yuanfei Shi, Yanchun Zhao, Yi Xu, Jianai Sun, Xiaolong Zheng, De Zhou, Jie Jin, Hongyan Tong, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 6238.

https://doi.org/10.1182/blood-2024-202205

Published: 2024

Journal Articles

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Xuewu Zhang, Haitao Meng, Gaixiang Xu, Min Yang, Wanzhuo Xie, Juying Wei, Liya Ma, Xingnong Ye, Liping Mao, Wenyuan Mai, Chunmei Yang, Yanling Ren, Hongyan Tong, Yanan Zhu, Xiang Zhang, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6772.

https://doi.org/10.1182/blood-2024-203639

Published: 2024

Journal Articles

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Huafeng Wang, Xiaolong Zheng, Wenjuan Yu, De Zhou, Chunmei Yang, Xinping Zhou, Liping Mao, Haitao Meng, Liangshun You, Min Yang, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2024-197872

Published: 2024

Journal Articles

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Blood (2023) 142 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2023-184470

Published: 2023

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial

Shanshan Suo, Wen-Juan Yu, Ying Lu, Jiejing Qian, Liping Mao, Jin Wang, Lijing Shen, Bingzong Li, Huafeng Wang, Wenyuan MAI, Wanzhuo Xie, Xiaomin Wang, Dan Zhao, Yuanfang Liu, Chuan He, Jie Jin

Blood (2023) 142 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2023-191190

Published: 2023

Journal Articles

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6001.

https://doi.org/10.1182/blood-2023-186048

Published: 2023

Journal Articles

Chidamide As Maintenance in Peripheral T-Cell Lymphoma for Patients in Response after Induction Therapy: A Single Center Retrospective Study

Yanan Zhu, Juying Wei, Chunmei Yang, Wanzhuo Xie, Yanhong Tong, Wen-Juan Yu, Jie Jin

Blood (2023) 142 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2023-180495

Published: 2023

Journal Articles

The Prognostic Value of Common Cardiovascular Biomarkers in the Survival of Patients with DLBCL

Yi Xu, Yuanfei Shi, Jianai Sun, Xiaolong Zheng, Xueying Li, Jinghan Wang, Wenjuan Yu, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2023) 142 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2023-186066

Published: 2023

Journal Articles

Real Event Analysis of the Efficacy and Safety of Polatuzumab Vedotin Combination Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Yuanfei Shi, Yi Xu, Jinghan Wang, Xiaolong Zheng, Xueying Li, Jie Jin, Hongyan Tong, Wanzhuo Xie

Blood (2023) 142 (Supplement 1): 6100.

https://doi.org/10.1182/blood-2023-186156

Published: 2023

Journal Articles

The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Yuanfei Shi, Jinghan Wang, Xueying Li, Xiaolong Zheng, Wen-Juan Yu, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2023) 142 (Supplement 1): 6224.

https://doi.org/10.1182/blood-2023-186591

Published: 2023

Journal Articles

The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Min Yang, Huafeng Wang, Wenjuan Yu, Liangshun You, Haitao Meng, Chunmei Yang, Xinping Zhou, Li Li, De Zhou, Xiujing Ye, Hong-hu Zhu, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2022) 140 (Supplement 1): 3756.

https://doi.org/10.1182/blood-2022-158723

Published: 2022

NARROW

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Efficacy and Safety of Glofitamab Combined with Tislelizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Mitoxantrone Hydrochloride Liposome in Combination with Cytarabine and Venetoclax (MAV) Regimen in Relapsed or Refractory Acute Myeloid Leukemia

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Effects and Molecular Mechanism of Inhibiting p53 Signaling Pathway By NSUN6 on the Resistance to BCL-2 Inhibitor for Diffuse Large B-Cell Lymphoma

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Chidamide As Maintenance in Peripheral T-Cell Lymphoma for Patients in Response after Induction Therapy: A Single Center Retrospective Study

The Prognostic Value of Common Cardiovascular Biomarkers in the Survival of Patients with DLBCL

Real Event Analysis of the Efficacy and Safety of Polatuzumab Vedotin Combination Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only